ArticleOncology and therapy2023

Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP).

Adrián Alegre et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.